Caries Transmission Prevention in Alaska Native Infants
Terminated
National Institute of Dental and Craniofacial Research (NIDCR)
Phase 3
2003-04-01
The purpose of this study is to conduct a community based, randomized control trial to
determine if the use of chlorhexidine mouth rinse and xylitol-sweetened chewing gum will
reduce the vertical transmission of caries between Alaska Native mothers to their infants.
Caries Transmission Prevention in Alaska Native Infants
Terminated
University of Washington
Phase 3
2003-04-01
The purpose of this study is to conduct a community based, randomized control trial to
determine if the use of chlorhexidine mouth rinse and xylitol-sweetened chewing gum will
reduce the vertical transmission of caries between Alaska Native mothers to their infants.
Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome
Completed
Massachusetts General Hospital
Phase 2/Phase 3
2004-04-01
Metabolic syndrome is associated with increased inflammatory cytokines and reduced
adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned
that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin,
improving the inflammatory milieu associated with metabolic syndrome.
Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome
Completed
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2/Phase 3
2004-04-01
Metabolic syndrome is associated with increased inflammatory cytokines and reduced
adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned
that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin,
improving the inflammatory milieu associated with metabolic syndrome.
Macrolide Maintenance Therapy in Chronic Obstructive Pulmonary Disease
Completed
Amphia Hospital
N/A
2010-05-01
To assess whether maintenance treatment with macrolide antibiotics in COPD patients with
three or more exacerbations in the preceding year of inclusion can decrease the exacerbation
rate in the year of treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
